Summary Counter-irritation (CI) triggered by different non-specific irritant stimuli delayed the growth of a murine tumour of non-detected immunogenicity. The syngeneic LB tumour transplant by itself also induced CI and decreased the number of leukocytes migrating to a secondary s.c. irritant stimulus, e.g. sponge or carrageenan. On the other hand, partial inhibition of cell migration by treatment with either 0.5 mg kg' indomethacin or 0.3 mg kg-' piroxicam retarded LB tumour growth, presumably by a mechanism unrelated to inhibition of immune responses by PGE2. It is suggested that Cl may play a role in the early stages of concomitant resistance.
Activated macrophages (MO) can display cytotoxicity against tumour cells and are considered an important host defence mechanism against neoplasia. However, M4s may play a dual role in the growth of solid angiogenesis-dependent tumours (Folkman, 1985) since their presence at the site of incipient neoplastic growth is essential for neovascularisation. Although the mechanisms involved remain obscure, a regulatory effect of inflammation on different stages of tumour growth has been proposed (Normann et al., 1988) . In support of this hypothesis, Prehn & Prehn (1987) suggested that immunogenic neoplastic cells may benefit from interaction with inflammatory Mos. Furthermore, it has been reported that treatment with non-steroidal anti-inflammatory agents (NSAIA) may restrict the growth of tumours of varying degrees of immunogenicity, probably by inhibiting prostaglandin E2 synthesis (Goodwin & Ceuppens, 1983) . Physiological anti-inflammation is mediated by complex and not completely understood mechanisms. One of these, CI, was defined as the ability of local irritation to exert an anti-inflammatory effect at a remote site in the body (Atkinson & Hicks, 1975) . CI is non-specific and, as recently suggested, may inhibit the growth of immunogenic tumours (Normann et al., 1985b (Normann et al., , 1987 . This study was aimed at investigating the effect of CI and the administration of NSAIA on the growth of a solid tumour on non-detected immunogenicity.
Materials and methods

Animals
Male and female 8-week-old F, hybrids (Balb/c x DBA/2) were raised in our animal house under standard conditions and fed ad libitum with Cargill (Buenos Aires) pelleted food and acidified tap water (final concentration, 50 mM HCI, pH = 2.8).
Tumour
The T-helper cell leukaemia (LB), which arose spontaneously in a 6-month-old Balb/c male mouse (Ruggiero et al., 1985) was, at the beginning of this study, in its 58th s. 
Statistics
Statistical analysis was performed using the Epistat package (T.L. Gustafson, Round Rock, TX, USA) in a personal computer. Data with normal distribution and homogeneous variances were compared by analysis of variance using the ANOVA program. Otherwise, data were analysed by the rank sum test using the Ranktest program.
Results
To determine whether CI affected tumour growth in vivo, a polystyrene sponge was implanted s.c. to generate local inflammation, followed 24 h later by 106 tumour cells s.c. in the contralateral flank. Tumour growth was delayed ( Figure  1 ) but tumour incidence and survival rates were not modified. Tumour growth was also retarded by anti-inflammatory treatment ( Figure 2 ) and death of the mice (Table I) was delayed by 10 days. The tumour grew in all eight control mice while it didn't grow in two out of eight piroxicamtreated mice. When treatment with piroxicam was continued beyond day 24 after tumour challenge, the solid tumour never developed although most animals died due to generalised infiltration by LB cells. In another experiment, 5-day-old tumours developing from a 106 cell inoculum were excised, and the weight determined in untreated (3.38 ± 0.27 g) and piroxicam-treated (1.25 ± 0.09 g) mice. The number of cells recovered from tumours of control mice was 2.0 x 108 while 1.3 x 108 cells were recovered from tumours of treated mice. The smaller size of the tumours in treated mice, consequently, does not seem to be related to a decrease in tumoral oedema due to anti-inflammatory treatment. Moreover, incubation of the tumour mass at 60°C until constant weight revealed that the weight loss was 67% in untreated and 83% in treated mice, which indicates that the water relative content was higher in treated than in control mice.
The effects on inflammation of either CI triggered by different irritants or NSAIA treatment were evaluated by Days after tumour inoculation Figure 4 The effect of an LB solid tumour on oedema induced by carrageenan injection in the hind-footpad (a), and on cell migration into the sponge implanted s.c. (b). Mice bearing a tumour were evaluated after challenge with 106 and 107 LB cells respectively. Each point represents the arithmetic mean ± s.e.m. from eight mice, (*) significant difference when compared with controls (see text for level of significance). Shaded areas represent the arithmetic mean ± s.e.m of the hind limb weight of (a), and the cell number retrieved from (b) unchallenged mice. migration. Paw oedema was diminished on day 4 or 6 after inoculation of 106 LB cells (P = 0.0069) when compared with controls ( Figure 4a ). The number of cells recovered from the sponges were decreased by days 5 and 6 after tumour implantation (P = 0.029 and P = 0.0004, respectively). On day 7 a rebound effect was observed and the number of cells was increased (P = 0.029) (Figure 4b ).
The effect of the tumour on cell migration towards an inflammatory i.d. stimulus (carrageenan) was confirmed histologically. In control mice, microscopy of skin explants revealed inflammation characterised by diffuse infiltration involving dermis and subcutaneous fatty tissue (Figure 5a ). The infiltrate contained predominantly mononuclear cells (inset of Figure Sa) . In contrast, mice bearing a solid LB tumour of 7 days growth exhibited inflammation in a band pattern restricted to a thin layer localised between dermis and fatty subcutaneous tissue (inset Figure 5b) . When carrageenan was administered to mice bearing a 10-day tumour, severe inflammation developed, with intense infiltration localised in a band between dermis and fatty subcutaneous tissue, with only diffuse infiltration in these two areas ( Figure  Sc) . At higher magnification, the density of the mononuclear cell infiltrate was even greater than that seen in untreated mice (inset Figure Sc vs. inset Figure Sa) .
Discussion
There are two main aspects to be discussed in the light of the results from this study. One relates to CI as a natural mechanism of tumour growth inhibition, and the other is the therapeutic application of NSAIA to obtain inhibition of Figure 5 Histopathological analysis of skin explants from the area where 1% carrageenan was injected intradermally to control mice (a), mice bearing a 7-day-old solid LB tumour (b) and mice bearing a 10-day-old solid LB tumour (c) (magnification x 2.5).
The insets depict, at higher magnification ( x 25) the infiltrated region of the tissue in each case. Representative photomicrographs from groups of six mice are shown.
non-immunogenic tumour growth.
Inhibition of inflammation by a secondary irritant stimulus due to CI has been demonstrated in diverse experimental systems. Supporting our results, there is previous evidence suggesting that inflammatory responses may be affected by the presence of a tumour. Snyderman et al. (1976) showed that experimental transplantation of a benzopyrene-induced sarcoma in rats prevented M4 accumulation during inflammation. Furthermore, Normann et al. (1985a) have shown that transplantation of syngeneic tumour cells depressed MO inflammatory responses, probably through an increase in the endogenous levels of corticosterone (Normann et al., 1988 ). Our data demonstrate that, as with immunogenic tumours, a cancer of immunogenicity below our level of detection can also induce CI.
At least two important features of tumour-M4 interaction should be considered. The first is that cellular immune responses occurring within a tumour can destroy it (Zbar et al., 1970) . In fact, immunologically mediated tumour killing is frequently associated with an influx of MO to the site of neoplastic growth (Shin et al., 1975 (Folkman & Cotran, 1976) . There were two significant findings in our study: (i) inhibition of tumour growth by an inflammatory focus located away from the site of LB cell grafting; and (ii) inhibition of blood cell migration induced by the LB tumour towards the site where an irritant Htad been inoculated. Because the LB tumour itself can both induce CI and be affected by antiinflammation, it would be expected that a primary tumour inoculum could also inhibit the growth of a secondary inoculum of the same tumour. Inhibition of experimental metastases by a primary tumour has been observed in laboratory animals (Gorelik et al., 1978) and defined as 'concomitant immunity' (Gorelik et al., 1981) or, more appropriately, 'concomitant resistance' (Meiss et al., 1986) , a non-specific, rapid, dose-dependent and complex phenomenon. The molecular basis of concomitant resistance remains unknown, but it is speculated that several mechanisms may be acting either simultaneously or sequentially. It has been demonstrated in our laboratory that, although non-immunogenic, the LB tumour can induce concomitant resistance (Ruggiero et al., 1985) , and that inhibition of secondary LB tumour growth by the presence of a primary tumour is abrogated if inflammatory M4s are injected into the secondary site of tumour cell implantation (Bustuoabad et al., 1984 Administration of different NSAIAs as a single agent to inhibit tumour growth has been attempted (Humes et al., 1974; Lynch et al., 1978; Bennet et al., 1979 Bennet et al., , 1982 Bennet et al., , 1985 Narisawa et al., 1981; Panje, 1981; Pollard & Luckert, 1981; McCormick & Moon, 1983; Caignard et al., 1984; Fulton, 1984; Rubio, 1984; McCormick et al., 1985; Kort et al., 1986) . Piroxicam treatment inhibits colon carcinogenesis (Pollard & Luckert, 1983; Reddy et al., 1987) in rats, and in combination with an anti-neoplastic agent it has also been used in man (Braun et al., 1987) . The conflicting results obtained in these studies may be because of (i) a wide variety of spontaneous and induced tumours used experimentally; (ii) the tumours being transplanted in different sites; (iii) different animal species being used; (iv) NSAIA treatment being started at different times, before or after tumour challenge; and (v) NSAIAs being administered alone or in combination with other drugs (Caignard et al., 1984) . The major trend from these studies, however, is that NSAIA can inhibit tumour growth. Because high levels of PGE2 secreted by immunogenic tumours can interfere with immune responses against tumour cells (Normann et al., 1987) , it has been postulated that the anti-tumour activity of NSAIAs may be partly due to restoration of immune functions following inhibition of PGE2 synthesis (Lynch et al., 1978; Robertson et al., 1988) . Other mechanisms which may explain the antitumour activity of NSAIAs include inhibition of blood cell migration, as shown in this study, and the ability of NSAIAs, including piroxicam, to form stable copper complexes (Weser et al., 1982) , an important angiogenic factor necessary for neovascularisation (Ziche et al., 1982) .
It can be concluded that a syngeneic tumour of nondetected immunogenicity can induce CI, which may play a role in the early stages of concomitant resistance, and that treatment with NSAIA delays LB tumour growth in vivo.
Further studies ar required to ascertain the usefulness of NSAIA treatment to prevent or delay the appearance of metastases.
